{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:25:58Z","timestamp":1790220358085,"version":"4.1.0"},"reference-count":77,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,10,27]],"date-time":"2024-10-27T00:00:00Z","timestamp":1729987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The treatment landscape for relapsed\/refractory follicular lymphoma (RR\u2010FL) is marked by a pivotal debate between chimeric antigen receptor T\u2010cell (CAR\u2010T) therapy and bispecific antibodies (BsAbs). While both CAR\u2010T therapy and BsAbs target similar immunobiology and molecular markers, their efficacy comparisons are hindered by the lack of direct clinical trial comparisons. Key trials, such as the ZUMA\u20105 study, underscore axicabtagene ciloleucel (axi\u2010cel)'s efficacy in treating RR\u2010FL, achieving a 79% complete response rate with a median duration of response exceeding 3\u2009years. Similarly, lisocabtagene maraleucel (liso\u2010cel) in the TRANSCEND FL study reports a 94% complete response rate, emphasizing robust outcomes in heavily pretreated patients. Among BsAbs, mosunetuzumab showed promise in the GO29781 trial, with a 62% overall response rate in heavily pretreated RR\u2010FL patients. Thus, CAR\u2010T therapy offers potential curative benefits with a single infusion. However, its efficacy is tempered by significant adverse events such as cytokine release syndrome (CRS), neurotoxicity, and cytopenias, requiring specialized management and patient monitoring. In contrast, BsAbs provide a more tolerable treatment option counterbalancing by lower response rates and frequent dosing requirements. Personalized treatment strategies are crucial because of these distinct efficacy and safety profiles. When considering cost\u2010effectiveness, both therapies need to be evaluated in the context of their clinical outcomes and quality of life improvements. Cost\u2010effectiveness considerations are essential; while CAR\u2010T therapies incur higher initial costs, their potential for long\u2010term remission may mitigate expenses associated with repeated treatments or hospitalizations. Future research into resistance mechanisms and optimal therapeutic sequencing will further refine RR\u2010FL management strategies.<\/jats:p>","DOI":"10.1111\/ejh.14335","type":"journal-article","created":{"date-parts":[[2024,10,27]],"date-time":"2024-10-27T04:14:37Z","timestamp":1730002477000},"page":"4-16","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Comparative Analysis of Bispecific Antibodies and\n                    <scp>CAR<\/scp>\n                    T\u2010Cell Therapy in Follicular Lymphoma"],"prefix":"10.1111","volume":"114","author":[{"given":"Fortunato","family":"Morabito","sequence":"first","affiliation":[{"name":"Gruppo Amici Dell'Ematologia Foundation\u2014GrADE  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica Antonia","family":"Martino","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Onco\u2010Hematology AO of Cosenza  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elena","family":"Nizzoli","sequence":"additional","affiliation":[{"name":"Hematology Unit Azienda USL\u2010IRCSS di Reggio Emilia  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Talami","sequence":"additional","affiliation":[{"name":"Hematology Unit Azienda USL\u2010IRCSS di Reggio Emilia  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Pozzi","sequence":"additional","affiliation":[{"name":"Hematology Unit Azienda USL\u2010IRCSS di Reggio Emilia  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Martino","sequence":"additional","affiliation":[{"name":"Department of Hemato\u2010Oncology and Radiotherapy, Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO) Grande Ospedale Metropolitano \u201cBianchi\u2010Melacrino\u2010Morelli\u201d  Reggio Calabria Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Neri","sequence":"additional","affiliation":[{"name":"Scientific Directorate Azienda USL\u2010IRCCS di Reggio Emilia  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5256-0726","authenticated-orcid":false,"given":"Massimo","family":"Gentile","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Onco\u2010Hematology AO of Cosenza  Cosenza Italy"},{"name":"Department of Pharmacy, Health and Nutritional Science University of Calabria  Rende Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,10,27]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24937"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70027-0"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.4474"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13895"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.1652"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01073"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15720"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00843"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614598"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0138"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281421"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010263"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100992"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00775"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.626616"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7059"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011994"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000905"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01084-4"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2020.11.058"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2015.02.008"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2011.06.012"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2014.93"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0161"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-741058"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718395"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00931"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00335-7"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148778"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00166-2"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158404"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01749-5"},{"key":"e_1_2_9_37_1","doi-asserted-by":"crossref","unstructured":"\u201cFDA Grants Accelerated Approval to Mosunetuzumab\u2010axgb for Relapsed or Refractory Follicular Lymphoma \u201dNews release US Food and Drug Administration accessed March 21 2023 https:\/\/doi.org\/10.1182\/bloodadvances.2022009260.","DOI":"10.1182\/bloodadvances.2022009260"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157691"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159640"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-145694"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157463"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010179906"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1953016"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03175"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148778"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19668"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010158232"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(22)00072\u20102"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf8621"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1399544"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1188049"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature22395"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.2.720"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403302"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz1863"},{"issue":"12","key":"e_1_2_9_56_1","first-page":"640","article-title":"Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma","volume":"3","author":"Mart\u00ednez Bedoya D.","year":"2021","journal-title":"Frontiers in Immunology"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.32604\/or.2024.049792"},{"key":"e_1_2_9_58_1","unstructured":"Food and Drug Administration \u201cFDA Approves Axi\u2010Cel for Relapsed\/Refractory Indolent Follicular Lymphoma \u201d2021 https:\/\/www.onclive.com\/view\/fda\u2010approves\u2010axi\u2010cel\u2010for\u2010relapsed\u2010refractory\u2010indolent\u2010follicular\u2010lymphoma."},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-186548"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(21)00591\u2010X"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021243"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2030164"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7579"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021567"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03175-4"},{"key":"e_1_2_9_67_1","unstructured":"\u201cFDA Grants Accelerated Approval to Lisocabtagene Maraleucel for Follicular Lymphoma \u201d FDA accessed May 15 2024 https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010grants\u2010accelerated\u2010approval\u2010lisocabtagene\u2010maraleucel\u2010follicular\u2010lymphoma."},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.06.016"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-178786"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010186842"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010182244"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.03.2493"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.11.008"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1412002"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022432"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157473"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010024\u201003084\u20106"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021672"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14335","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T09:02:11Z","timestamp":1757322131000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,27]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1111\/ejh.14335"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14335","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,27]]},"assertion":[{"value":"2024-08-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}